FMI Immune Checkpoint Inhibitors Market Value Share, A | Page 5

Immune Checkpoint Inhibitors Market Immune Checkpoint Inhibitors Market: Overview The immune checkpoint inhibitor market is driven by the need to address the rising rate of cancer prevalence thereby affecting the country healthcare cost. In UK, lung cancer is the leading cause of cancer related death. The survival rate past five years has only being 9% after the person is diagnosed with lung cancer. The new form of immunotherapy based on the inhibition of programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) receptors has shown hope as a therapy option for lung cancer. Immune Checkpoint Inhibitors Market: Region-wise Outlook In terms of geography, immune checkpoint inhibitors market has been divided into five regions including North- America, Asia- Pacific and Middle-East & Africa, Latin America and Europe. The number of clinical trials and research funding is relatively high in North America, making it the dominant region in terms of revenue in the immune checkpoint inhibitors market. In September 2014, Merck received accelerated FDA approval for its Keytruda molecule to treat patient with advanced melanoma. The company is forming global alliances with other companies to co-develop Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3326 immnuo-oncology research and expand its oncology business. ©2015 Future Market Insights, All Rights Reserved 5